+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07336732

Phase IIIII Study of Andamertinib With or Without Platinum Chemotherapy Compared to Platinum Chemotherapy Alone in Adults With Advanced Non-Squamous NSCLC Having Atypical EGFR Mutations

Led by Avistone Biotechnology Co., Ltd. · Updated on 2026-03-20

40

Participants Needed

1

Research Sites

113 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemotherapy compared to platinum-based chemotherapy alone in patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC that has specific EGFR atypical mutations. This open-label, randomized, multicenter phase IIIII trial includes participants who have not received prior systemic therapy. The study is designed in two stages phase II for dose exploration and phase III as the pivotal stage. The study involves three phases a Screening Phase from Day -28 to -1, a Treatment Phase continuing until treatment discontinuation, and a Follow-up Phase including the end of treatment visit, end of study visit, safety follow-up, and survival follow-up. Participants receive Andamertinib with or without platinum-based chemotherapy given orally once daily or platinum-based chemotherapy injections once every 21 days. The study monitors treatment regimens and safety over time. Participants will undergo multiple assessments including evaluation of treatment-emergent adverse events for up to 3 years, measurement of objective response rate, duration of response, disease control rate, progression-free survival, and overall survival rates. Pharmacokinetic characteristics of Andamertinib are assessed across specific treatment cycles. Safety and tolerability are closely monitored during treatment and follow-up, with the entire participation spanning several years depending on individual treatment and outcomes.

CONDITIONS

Brief Title

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Research Team

H

Haimeng Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here